

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
RLL-261US2

In Re Application Of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/520,726	07/08/2003	TBA	026815	TBA	

Title:  
**HMG CoA-REDUCTASE INHIBITORS**

Address to:  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**RLL-261US2**

In Re Application of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/520,726	07/08/2003	TBA	026815	TBA	

Title: **HMG CoA-REDUCTASE INHIBITORS**

### Payment of Fee

**(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))**

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

### Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

**(Date)**

**Signature**

***Typed or Printed Name of Person Signing Certificate***

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

**Signature of Person Mailing Correspondence**

***Typed or Printed Name of Person Mailing Certificate***

**\*This certificate may only be used if paying by deposit account.**

William D. Hare  
Signature

**Dated: February 17, 2006**

**William D. Hare**  
**Reg. No. 44,739**  
**Ranbaxy Inc.**  
**600 College Road East, Suite 2100**  
**Princeton, NJ 08540**  
**Tel.: (609) 720-5378**  
**Fax: (609) 514-9779**

CC:

<b>INFORMATION DISCLOSURE CITATION</b>	Docket No.: RLL-201US2	Serial No.: 10/520,726
	Applicants: KUMAR <i>et al.</i>	
	Filed: 1/7/2005	Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,681,893	7/21/1987	Roth	514	422	
	A2	5,273,995	12/28/1993	Roth	514	422	
	A3	5,385,929	1/31/1995	Bjorge <i>et al.</i>	514	422	
	A4	5,298,627	3/29/1994	Butler <i>et al.</i>	548	517	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	C1	Lea and McTavish, "Atorvastatin. A Review of its Pharmacology and Therapeutic Potential in the Management of Hyperlipidaemias", <i>Drugs</i> , 53(5):828-847 (1997)					
	C2	Kubo and Strott, "Differential Activity of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in Zones of the Adrenal Cortex", <i>Endocrinology</i> , 120(1):214-221 (1987)					
	C3	Heller and Gould, "Solubilization and Partial Purification of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase", <i>Biochemical and Biophysical Research Communications</i> , 50(3):859-865 (1973)					
	C4	C.B. Reese, "Chapter 3 - Protection of Alcoholic Hydroxyl Groups and Glycol Systems" <i>Protective Groups in Organic Chemistry</i> , Edited by J.F.W. McOmie, Plenum Press, New York, NY (1973)					

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.